Testing an eye imaging drug during retinal blood-vessel photos
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older (able to consent).
- If you’re able to become pregnant: you’re not pregnant and you will use reliable birth control during the study (and follow the study rules).
- If you’re male: you agree to use birth control or abstain starting on the dosing day and for at least 7 days after.
- You can follow all study visits and instructions, including eye imaging (fundus photographs).
- You’re willing to sign an informed consent form.
- You have a current history of a retinal or choroidal blood-vessel condition (at least 5 people are being enrolled with these conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This study uses a special, high-resolution camera to take detailed pictures of the back of the eye. It is testing the camera's ability to see changes in the retina for people who are healthy or have age-related macular degeneration, diabetic retinopathy, or other conditions that affect autofluorescence patterns.
This research study tests a new camera technology that takes detailed pictures of the back of your eye (retina) to better understand eye diseases. Researchers want to compare images from people with eye conditions like diabetes-related eye disease, glaucoma, or age-related macular degeneration with healthy volunteers to see how the new imaging works.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This study uses detailed eye imaging to look for patterns that may go along with conditions like Alzheimer’s disease, memory problems, multiple sclerosis, or eye/vascular issues. It may help researchers better understand how eye findings relate to health and disease.
This study looks at a specific lab marker (sCD160) in blood and eye fluids to see how it relates to poor blood flow in the retina. You may be asked for samples taken during eye surgery to help doctors understand the disease better.
Hear when a new Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.